Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v2.4.0.8
Consolidated Balance Sheets (Unaudited) (USD $)
Sep. 30, 2013
Dec. 31, 2012
Current assets:    
Cash and cash equivalents $ 529,895 $ 62,296
Account receivable net of allowance for doubtful accounts $61,973 and $46,119, respectively 50,281 784,733
Finance receivables, net 311,714   
Inventories 1,726,450 1,507,009
Prepaid expenses and other current assets 207,661 120,210
Total current assets 2,826,001 2,474,248
Property and equipment, net 3,133,216 3,333,919
Due from purchaser of Glyderm assets 400,000   
Deferred financing costs, net 10,169 10,573
Goodwill 1,026,984 1,026,984
Intangibles, net 148,477 190,894
Assets of discontinued operations 51,843 203,149
Total Noncurrent Assets 4,770,689 4,765,519
Total Assets 7,596,690 7,239,767
Current liabilities:    
Account payable 209,060 589,468
Accrued expenses and other current liabilities 3,953,411 3,106,332
Accrued interest 539,256 286,382
Notes payable - shareholder    1,099,715
Convertible notes payable 2,255,380 1,472,152
Deferred income tax 102,022 102,022
Derivative instruments 8,029,003 919,394
Current portion of long term debt 165,623 181,752
Liabilities of discontinued operations 33,430 168,296
Total current liabilities 15,287,185 7,925,513
Long Term Debt 2,764,081 2,894,579
Shareholders' deficiency    
Common stock, $.001 par value, 100,000,000 shares authorized, 70,111,100 and 63,142,969 shares issued and outstanding at September 30, 2013, and December 31, 2012, respectively 70,111 63,143
Additional paid-in capital 11,133,642 10,484,611
Accumulated deficit (21,658,329) (14,128,079)
Total shareholders' deficiency (10,454,576) (3,580,325)
Total liabilities and shareholders' deficiency $ 7,596,690 $ 7,239,767